EGFR+, epidermal growth factor receptor positive; mNSCLC, metastatic non-small cell lung cancer; PFS, progression-free survival.

References: 1. Sequist LV, et al. J Clin Oncol. 2013;31(27):3327-3334. 2. Rosell R, et al. Lancet Oncol. 2012;13(3):239-246. 3. Wu Y-L, et al. Lancet Oncol. 2017;18(11):1454-1466. 4. Park K, et al. Lancet Oncol. 2016;17(5):577-589. 5. Soria JC, et al. N Engl J Med. 2018;378(2):113-125. 6. Saito H, et al. Lancet Oncol. 2019;20(5):625-636. 7. Nakagawa K, et al. Lancet Oncol. 2019;20(12):1655-1669. 8. Passaro A, et al. Nat Cancer. 2021;2(4):377-391.